Galenica Group reported a 5.0% revenue growth in the first half of 2025, driven by strong demand for prescription medications and the acquisition of Labor Team, enhancing its service offerings in the Swiss healthcare market.

Target Information

Galenica Group has reported strong financial growth for the first half of 2025, with revenue increasing by 5.0% to CHF 1,995.4 million. This growth has been driven by the "Products & Care" segment, which saw a growth of 4.6%, and the "Logistics & IT" segment which recorded an increase of 5.5%. Notably, Galenica's performance has outpaced that of the overall pharmaceutical market, which grew by 4.8%, and the consumer healthcare market, which only saw a modest increase of 0.6%.

The significant revenue growth is attributed mainly to a high demand for prescription medications, particularly GLP-1-based weight loss drugs, alongside products related to a severe flu season early in the year. This robust performance was achieved despite having one fewer selling day compared to the previous year.

Industry Overview in Switzerland

The pharmaceutical industry in Switzerland continues to thrive, characterized by a stable regulatory environment and high levels of innovation. According to recent statistics from IQ